Citations (144)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Sana Alam, Zarina Arif & Khursheed Alam. (2015) Glycated-H2A histone is better bound by serum anti-DNA autoantibodies in SLE patients: Glycated-histones as likely trigger for SLE?. Autoimmunity 48:1, pages 19-28.
Read now
Read now
Paula I Burgos & Graciela S Alarcón. (2009) Thrombosis in systemic lupus erythematosus: risk and protection. Expert Review of Cardiovascular Therapy 7:12, pages 1541-1549.
Read now
Read now
Dolores Puente, Gonzalo Pombo & Ricardo Forastiero. (2009) Current management of antiphospholipid syndrome-related thrombosis. Expert Review of Cardiovascular Therapy 7:12, pages 1551-1558.
Read now
Read now
Gerard Espinosa & Ricard Cervera. (2009) Thromboprophylaxis and obstetric management of the antiphospholipid syndrome. Expert Opinion on Pharmacotherapy 10:4, pages 601-614.
Read now
Read now
S Jacobsen, J Petersen, S Ullman, P Junker, A Voss, J. M Rasmussen, U Tarp, L. H Poulsen, G van Overeem Hansen, B Skaarup, T. M Hansen, J Pødenphant, P Halberg. (1999) Mortality and Causes of Death of 513 Danish Patients with Systemic Lupus Erythematosus. Scandinavian Journal of Rheumatology 28:2, pages 75-80.
Read now
Read now
Articles from other publishers (139)
Saleha Dar, Sabina Koirala, Arooba Khan, Mounika Deepthi Bellary, Arya V Patel, Bejoi Mathew, Rahul Singh, Nahida Baigam, Waleed Razzaq, Zain U Abdin & Uzzam Ahmed Khawaja. (2023) A Comprehensive Literature Review on Managing Systemic Lupus Erythematosus: Addressing Cardiovascular Disease Risk in Females and Its Autoimmune Disease Associations. Cureus.
Crossref
Crossref
Cecilia B. Chighizola, Francesca Pregnolato, Danieli Andrade, Maria Tektonidou, Vittorio Pengo, Guillermo Ruiz‐Irastorza, H. Michael Belmont, Maria Gerosa, Paul Fortin, D. Ware Branch, Laura Andreoli, Michelle A. Petri, Ricard Cervera, Jason S. Knight, Rohan Willis, Maria Efthymiou, Hannah Cohen, Doruk Erkan & Maria Laura Bertolaccini. (2023)
Fluctuation of Anti–Domain 1 and Anti–
β
2
‐Glycoprotein
I Antibody Titers Over Time in Patients With Persistently Positive Antiphospholipid Antibodies
. Arthritis & Rheumatology 75:6, pages 984-995.
Crossref
Crossref
Michelle Petri, Martin Aringer, Isabelle Ayoub, Salem Almaani, Hermine Brunner, Maria Dall’Era, Mengdi Jiang, Richard Furie, Jessica Greco, Fiona Goldblatt, Jennifer Huggins, T. W. J. Huizinga, David Isenberg, Nicholas L. Li, R. C. Monahan, Samir V. Parikh, David Pisetsky, Abin P. Puravath, Brad Rovin, Daniel Wallace, Xuan Zhang & Lidan Zhao. 2023. A Clinician's Pearls & Myths in Rheumatology. A Clinician's Pearls & Myths in Rheumatology
167
212
.
Risa Wakiya, Kiyo Ueeda, Hiromi Shimada, Shusaku Nakashima, Tomohiro Kameda, Nobuyuki Miyatake, Mikiya Kato, Taichi Miyagi, Koichi Sugihara, Mao Mizusaki, Rina Mino, Norimitsu Kadowaki & Hiroaki Dobashi. (2022) Supplemental hydroxychloroquine therapy regulates adipokines in patients with systemic lupus erythematosus with stable disease. Clinical Rheumatology 41:11, pages 3345-3353.
Crossref
Crossref
Michelle Petri. (2022) Drug monitoring in systemic lupus erythematosus. Current Opinion in Pharmacology 64, pages 102225.
Crossref
Crossref
Maria G Lang, Carmen GC Vinagre, Eloisa Bonfa, Fatima R Freitas, Sandra G Pasoto, Tatiane S Brito, Luciana PC Seguro, Raul C Maranhão & Eduardo F Borba. (2022) Hydroxychloroquine increased cholesterol transfer to high-density lipoprotein in systemic lupus erythematosus: A possible mechanism for the reversal of atherosclerosis in the disease. Lupus 31:6, pages 659-665.
Crossref
Crossref
Meghan Anderson & H. Michael Belmont. (2022) Severe thrombotic events associated with pre-procedural interruption of anticoagulation in systemic lupus erythematosus with secondary antiphospholipid syndrome: Cases and literature review. Lupus 31:2, pages 261-267.
Crossref
Crossref
Carmine A. Ballarano & William H. Frishman. (2021) Cardiovascular Disease in Patients With Systemic Lupus Erythematosus. Cardiology in Review 29:6, pages 323-327.
Crossref
Crossref
Isabela Maria Bertoglio, Juliana Miranda de Lucena Valim, Danielle Daffre, Nádia Emi Aikawa, Clovis Artur Silva, Eloisa Bonfá & Michelle Remião Ugolini‐Lopes. (2021) Poor Prognosis of COVID‐19 Acute Respiratory Distress Syndrome in Lupus Erythematosus: Nationwide Cross‐Sectional Population Study Of 252 119 Patients. ACR Open Rheumatology 3:11, pages 804-811.
Crossref
Crossref
Chris R. Toy, Huijuan Song, Haikady N. Nagaraja, Julia Scott, Jessica Greco, Xiaolan Zhang, Chack-Yung Yu, James A. Tumlin, Brad H. Rovin, Lee A. Hebert & Daniel J. Birmingham. (2021) The Influence of an Elastase-Sensitive Complement C5 Variant on Lupus Nephritis and Its Flare. Kidney International Reports 6:8, pages 2105-2113.
Crossref
Crossref
Michelle Petri, Maximilian F. Konig, Jessica Li & Daniel W. Goldman. (2021) Association of Higher Hydroxychloroquine Blood Levels With Reduced Thrombosis Risk in Systemic Lupus Erythematosus. Arthritis & Rheumatology 73:6, pages 997-1004.
Crossref
Crossref
Rania Alhaj Ali, Hussein Halabi & Hani Almoallim. 2021. Skills in Rheumatology. Skills in Rheumatology
353
381
.
Edgard Torres dos Reis Neto, Adriana Maria Kakehasi, Marcelo de Medeiros Pinheiro, Gilda Aparecida Ferreira, Cláudia Diniz Lopes Marques, Licia Maria Henrique da Mota, Eduardo dos Santos Paiva, Gecilmara Cristina Salviato Pileggi, Emília Inoue Sato, Ana Paula Monteiro Gomides Reis, Ricardo Machado Xavier & José Roberto Provenza. (2020) Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases. Advances in Rheumatology 60:1.
Crossref
Crossref
Ruth Fernandez-Ruiz, Nicole Bornkamp, Mimi Y. Kim, Anca Askanase, Anna Zezon, Chung-E Tseng, H. Michael Belmont, Amit Saxena, Jane E. Salmon, Michael Lockshin, Jill P. Buyon & Peter M. Izmirly. (2020) Discontinuation of hydroxychloroquine in older patients with systemic lupus erythematosus: a multicenter retrospective study. Arthritis Research & Therapy 22:1.
Crossref
Crossref
Yu Zuo, Srilakshmi Yalavarthi, Kelsey Gockman, Jacqueline A. Madison, Johann E. Gudjonsson, J. Michelle Kahlenberg, W. Joseph McCune, Paula L. Bockenstedt, David R. Karp & Jason S. Knight. (2020) Anti–Neutrophil Extracellular Trap Antibodies and Impaired Neutrophil Extracellular Trap Degradation in Antiphospholipid Syndrome. Arthritis & Rheumatology 72:12, pages 2130-2135.
Crossref
Crossref
Ruth Fernandez‐Ruiz, Mala Masson, Mimi Y. Kim, Benjamin Myers, Rebecca H. Haberman, Rochelle Castillo, Jose U. Scher, Allison Guttmann, Philip M. Carlucci, Kristina K. Deonaraine, Michael Golpanian, Kimberly Robins, Miao Chang, H. Michael Belmont, Jill P. Buyon, Ashira D. Blazer, Amit Saxena & Peter M. Izmirly. (2020) Leveraging the United States Epicenter to Provide Insights on COVID‐19 in Patients With Systemic Lupus Erythematosus. Arthritis & Rheumatology 72:12, pages 1971-1980.
Crossref
Crossref
Muznay Khawaja, Laurence Magder, Daniel Goldman & Michelle A Petri. (2020) Loss of antiphospholipid antibody positivity post-thrombosis in SLE. Lupus Science & Medicine 7:1, pages e000423.
Crossref
Crossref
Joyce C. Chang, Rui Xiao, Andrea M. Knight, Stephen E. Kimmel, Laura M. Mercer-Rosa & Pamela F. Weiss. (2020) A population-based study of risk factors for heart failure in pediatric and adult-onset systemic lupus erythematosus. Seminars in Arthritis and Rheumatism 50:4, pages 527-533.
Crossref
Crossref
María del Carmen Zamora-Medina, Andrea Hinojosa-Azaola, Carlos A. Nuñez-Alvarez, Angel Gabriel Vargas-Ruiz & Juanita Romero-Diaz. (2018) Anti-RNP/Sm antibodies in patients with systemic lupus erythematosus and its role in thrombosis: a case-control study. Clinical Rheumatology 38:3, pages 885-893.
Crossref
Crossref
H. J. A. Carp. 2019. Evidence‐based Obstetrics and Gynecology. Evidence‐based Obstetrics and Gynecology
131
144
.
Andrea Fava & Michelle Petri. (2019) Systemic lupus erythematosus: Diagnosis and clinical management. Journal of Autoimmunity 96, pages 1-13.
Crossref
Crossref
Cristina Belizna, Francesca Pregnolato, Sebastien Abad, Jaume Alijotas-Reig, Howard Amital, Zahir Amoura, Laura Andreoli, Emmanuel Andres, Achile Aouba, Sule Apras Bilgen, Laurent Arnaud, Boris Bienvenu, Viktoria Bitsadze, Patrick Blanco, Miri Blank, Maria Orietta Borghi, Antonia Caligaro, Elisabeta Candrea, Valentina Canti, Laurent Chiche, Jean Marie Chretien, Jan Willem Cohen Tervaert, Laura Damian, Teresa Delross, Emmanuelle Dernis, Katrien Devreese, Aleksandra Djokovic, Enrique Esteve-Valverde, Maria Favaro, Céline Fassot, Raquel Ferrer-Oliveras, Alban Godon, Mohamed Hamidou, Milena Hasan, Daniel Henrion, Bernard Imbert, Pierre Yves Jeandel, Pascale Jeannin, Patrick Jego, Noemie Jourde-Chiche, Jamilya Khizroeva, Olivier Lambotte, Cédric Landron, Jose Omar Latino, Estibaliz Lazaro, Karina de Leeuw, Thomas Le Gallou, Levent Kiliç, Maarten Limper, Laurent Loufrani, Romain Lubin, Nadine Magy-Bertrand, Guillaume Mahe, Alexander Makatsariya, Thierry Martin, Christian Muchardt, Gyorgy Nagy, Loukman Omarjee, Pieter Van Paasen, Gilles Pernod, Florence Perrinet, Gilberto Pïres Rosa, Marc Antoine Pistorius, Amelia Ruffatti, Fatma Said, Patrick Saulnier, Damien Sene, Loic Sentilhes, Ova Shovman, Jean Sibilia, Crina Sinescu, Natasa Stanisavljevic, Ljudmila Stojanovich, Lai Shan Tam, Angela Tincani, Fréderic Tollis, Sebastian Udry, Marie Noelle Ungeheuer, Mathilde Versini, Ricard Cervera & Pier Luigi Meroni. (2018) HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome. Autoimmunity Reviews 17:12, pages 1153-1168.
Crossref
Crossref
Vítor Teixeira & Lai-Shan Tam. (2018) Novel Insights in Systemic Lupus Erythematosus and Atherosclerosis. Frontiers in Medicine 4.
Crossref
Crossref
Philip G. de Groot & Bas de Laat. (2017) Mechanisms of thrombosis in systemic lupus erythematosus and antiphospholipid syndrome. Best Practice & Research Clinical Rheumatology 31:3, pages 334-341.
Crossref
Crossref
Guillermo Ruiz-Irastorza & Munther Khamashta. 2017. Antiphospholipid Syndrome in Systemic Autoimmune Diseases. Antiphospholipid Syndrome in Systemic Autoimmune Diseases
231
241
.
Joan T. Merrill. 2017. Antiphospholipid Syndrome in Systemic Autoimmune Diseases. Antiphospholipid Syndrome in Systemic Autoimmune Diseases
193
214
.
Cameron G. McCarthy, Camilla F. Wenceslau, Styliani Goulopoulou, Safia Ogbi, Takayuki Matsumoto & R.Clinton Webb. (2016) Autoimmune therapeutic chloroquine lowers blood pressure and improves endothelial function in spontaneously hypertensive rats. Pharmacological Research 113, pages 384-394.
Crossref
Crossref
Alba Velo-García, Sara Guerreiro Castro & David A. Isenberg. (2016) The diagnosis and management of the haematologic manifestations of lupus. Journal of Autoimmunity 74, pages 139-160.
Crossref
Crossref
Hui Jen Ding, Alastair K. Denniston, Vijay K. Rao & Caroline Gordon. (2016) Hydroxychloroquine-related retinal toxicity. Rheumatology 55:6, pages 957-967.
Crossref
Crossref
César Magro-Checa, Elisabeth J. Zirkzee, Tom W. Huizinga & Gerda M. Steup-Beekman. (2016) Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives. Drugs 76:4, pages 459-483.
Crossref
Crossref
W. Joseph McCune & Tania Gonzalez-Rivera. (2015) Should very low doses of hydroxychloroquine and quinacrine be employed in combination for long-term maintenance of remission in systemic lupus to reduce the risk of ocular toxicity?. Current Opinion in Rheumatology 27:3, pages 213-215.
Crossref
Crossref
Cristina Belizna. (2015) Hydroxychloroquine as an anti-thrombotic in antiphospholipid syndrome. Autoimmunity Reviews 14:4, pages 358-362.
Crossref
Crossref
E. Lazaro, C. Richez & J. Seneschal. (2015) Lupus eritematoso sistémico. EMC - Aparato Locomotor 48:1, pages 1-17.
Crossref
Crossref
L. Arnaud, A. Mathian, E. Bruckert & Z. Amoura. (2014) Le risque cardiovasculaire au cours du lupus systémique. La Revue de Médecine Interne 35:11, pages 723-729.
Crossref
Crossref
Renata Baronaite Hansen & Søren Jacobsen. (2014) Infections Increase Risk of Arterial and Venous Thromboses in Danish Patients with Systemic Lupus Erythematosus: 5102 Patient-years of Followup. The Journal of Rheumatology 41:9, pages 1817-1822.
Crossref
Crossref
Maureen McMahon & Brian Skaggs. (2014) Pathogenesis and Treatment of Atherosclerosis in Lupus. Rheumatic Disease Clinics of North America 40:3, pages 475-495.
Crossref
Crossref
Nathalie Costedoat-Chalumeau, Bertrand Dunogué, Nathalie Morel, Véronique Le Guern & Gaëlle Guettrot-Imbert. (2014) Hydroxychloroquine: A multifaceted treatment in lupus. La Presse Médicale 43:6, pages e167-e180.
Crossref
Crossref
Zoran Todorovic, Branislava Medic, Gordana Basta-Jovanovic, Sanja Radojevic Skodric, Radan Stojanovic, Branislav Rovcanin & Milica Prostran. (2014) Acute Pretreatment with Chloroquine Attenuates Renal I/R Injury in Rats. PLoS ONE 9:3, pages e92673.
Crossref
Crossref
Aleksandra Matyja-Bednarczyk, Jakub Swadźba, Teresa Iwaniec, Marek Sanak, Sylwia Dziedzina, Adam Ćmiel & Jacek Musiał. (2014) Risk factors for arterial thrombosis in antiphospholipid syndrome. Thrombosis Research 133:2, pages 173-176.
Crossref
Crossref
Lynne C. Jones & Deborah McK. Ciombor. 2014. Osteonecrosis. Osteonecrosis
71
80
.
H Timlin & M Petri. (2013) Transient ischemic attack and stroke in systemic lupus erythematosus. Lupus 22:12, pages 1251-1258.
Crossref
Crossref
Nancy J. Olsen, Michele A. Schleich & David R. Karp. (2013) Multifaceted effects of hydroxychloroquine in human disease. Seminars in Arthritis and Rheumatism 43:2, pages 264-272.
Crossref
Crossref
Douglas J. Taatjes, Anthony S. Quinn, Jacob H. Rand & Bhanu P. Jena. (2013) Atomic force microscopy: High resolution dynamic imaging of cellular and molecular structure in health and disease. Journal of Cellular Physiology 228:10, pages 1949-1955.
Crossref
Crossref
David GarciaElie A. AklRichard Carr & Clive Kearon. (2013) Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review. Blood 122:5, pages 817-824.
Crossref
Crossref
Vijay Rao & Simon Bowman. (2013) Latest advances in connective tissue disorders. Therapeutic Advances in Musculoskeletal Disease 5:4, pages 234-249.
Crossref
Crossref
DM Wahezi, NT Ilowite, XX Wu, L Pelkmans, B Laat, LE Schanberg & JH Rand. (2013) Annexin A5 anticoagulant activity in children with systemic lupus erythematosus and the association with antibodies to domain I of β2-glycoprotein I. Lupus 22:7, pages 702-711.
Crossref
Crossref
Anthony S. Quinn, Xiao-Xuan Wu, Jacob H. Rand & Douglas J. Taatjes. (2012) Insights into the pathophysiology of the antiphospholipid syndrome provided by atomic force microscopy. Micron 43:8, pages 851-862.
Crossref
Crossref
Ibrahim A. Al-Homood. (2012) Thrombosis in Systemic Lupus Erythematosus: A Review Article. ISRN Rheumatology 2012, pages 1-6.
Crossref
Crossref
D. Saadoun, J.-C. Piette, D. Wahl & N. Costedoat-Chalumeau. (2012) Traitement du syndrome des anticorps antiphospholipides. La Revue de Médecine Interne 33:4, pages 217-222.
Crossref
Crossref
Ilan Ben-Zvi, Shaye Kivity, Pnina Langevitz & Yehuda Shoenfeld. (2011) Hydroxychloroquine: From Malaria to Autoimmunity. Clinical Reviews in Allergy & Immunology 42:2, pages 145-153.
Crossref
Crossref
DAWN M. WAHEZI, NORMAN T. ILOWITE, SWAPNIL RAJPATHAK & JACOB H. RAND. (2012) Prevalence of Annexin A5 Resistance in Children and Adolescents with Rheumatic Diseases. The Journal of Rheumatology 39:2, pages 382-388.
Crossref
Crossref
Alvaro Danza, Guillermo Ruiz-Irastorza & Munther Khamashta. (2012) Antiphospohlipid syndrome in obstetrics. Best Practice & Research Clinical Obstetrics & Gynaecology 26:1, pages 65-76.
Crossref
Crossref
Robert A. Sands. 2012. Lupus Erythematosus. Lupus Erythematosus
107
114
.
Xiao-Xuan Wu, Seth Guller & Jacob H. Rand. (2011) Hydroxychloroquine reduces binding of antiphospholipid antibodies to syncytiotrophoblasts and restores annexin A5 expression. American Journal of Obstetrics and Gynecology 205:6, pages 576.e7-576.e14.
Crossref
Crossref
Pál Soltész, György Kerekes, Henriett Dér, Gabriella Szücs, Sándor Szántó, Emese Kiss, Edit Bodolay, Margit Zeher, Orsolya Timár, Péter Szodoray, Gyula Szegedi & Zoltán Szekanecz. (2011) Comparative assessment of vascular function in autoimmune rheumatic diseases: Considerations of prevention and treatment. Autoimmunity Reviews 10:7, pages 416-425.
Crossref
Crossref
Michelle PETRI. (2011) Clinical research in systemic lupus erythematosus: immediate relevance to clinical practice. International Journal of Rheumatic Diseases 14:1, pages 1-5.
Crossref
Crossref
Tadej Avčin & Kathleen M. O’Neil. 2011. Textbook of Pediatric Rheumatology. Textbook of Pediatric Rheumatology
344
360
.
Nathalie Costedoat-Chalumeau, Gaëlle Leroux, Jean-Charles Piette & Zahir Amoura. 2011. Systemic Lupus Erythematosus. Systemic Lupus Erythematosus
1061
1081
.
Gerard Espinosa & Ricard Cervera. 2011. Systemic Lupus Erythematosus. Systemic Lupus Erythematosus
1027
1042
.
Richard Choi, Valarie Gendron, Mac McLaughlin, Jonathan Cahill, Fathima Qadeer & Syed A. Rizvi. 2011. Clinical Neuroimmunology. Clinical Neuroimmunology
375
389
.
Naoto Yokogawa & Joan M. Von Feldt. 2011. Geriatric Rheumatology. Geriatric Rheumatology
17
25
.
J. Szymezak, A. Ankri, A.-M. Fischer & L. Darnige. (2010) Hydroxychloroquine : une nouvelle approche thérapeutique des manifestations thrombotiques du syndrome des antiphospholipides. La Revue de Médecine Interne 31:12, pages 854-857.
Crossref
Crossref
Miroslav Mayer, Mislav Cerovec, Marko Radoš & Nada Čikeš. (2010) Antiphospholipid syndrome and central nervous system. Clinical Neurology and Neurosurgery 112:7, pages 602-608.
Crossref
Crossref
Mahmoud Reza Azarpazhooh, Naghmeh Mokhber, Elias Orouji, Brian R. Chambers, Mohammad Reza Hatef, Zahra Rezaieyazdi, Sima Sedighi, Mohsen Foroghipoor, Arash Velayati & Morteza Modares Gharavi. (2014) Microembolic Signals in Patients with Systemic Lupus Erythematosus. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 37:3, pages 371-375.
Crossref
Crossref
JH RandX-X. Wu, AS Quinn & DJ Taatjes. (2010) The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis. Lupus 19:4, pages 460-469.
Crossref
Crossref
Beverley J. Hunt. (2010) A novel antiphospholipid antibody agent?. Blood 115:11, pages 2124-2125.
Crossref
Crossref
Jacob H. RandXiao-Xuan WuAnthony S. QuinnAnthony W. AshtonPojen P. Chen, James J. Hathcock, Harry A. M. Andree & Douglas J. Taatjes. (2010) Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug. Blood 115:11, pages 2292-2299.
Crossref
Crossref
Hyejung Jung, Raja Bobba, Jiandong Su, Zhaleh Shariati-Sarabi, Dafna D. Gladman, Murray Urowitz, Wendy Lou & Paul R. Fortin. (2010) The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis & Rheumatism 62:3, pages 863-868.
Crossref
Crossref
Francesco Dentali & Mark Crowther. (2010) Antiphospholipid antibodies in critical illness. Critical Care Medicine 38, pages S51-S56.
Crossref
Crossref
Jean-Jacques Boffa, Jean-Philippe Rougier, Nicolas Noël & Pierre Ronco. (2009) Le risque cardiovasculaire accru du lupus : données physiopathologiques et thérapeutiques. Néphrologie & Thérapeutique 5:7, pages 595-602.
Crossref
Crossref
Bill Giannakopoulos & Steven A. Krilis. (2009) How I treat the antiphospholipid syndrome. Blood 114:10, pages 2020-2030.
Crossref
Crossref
Guillermo J. Pons-Estel, Graciela S. Alarcón, Gerald McGwinJr.Jr., Maria I. Danila, Jie Zhang, Holly M. Bastian, John D. Reveille & Luis M. Vilá. (2009) Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis & Rheumatism 61:6, pages 830-839.
Crossref
Crossref
Benjamin M. Greenberg. (2009) The Neurologic Manifestations of Systemic Lupus Erythematosus. The Neurologist 15:3, pages 115-121.
Crossref
Crossref
JP Dhar, J Andersen, L Essenmacher, J Ager, G Bentley & RJ Sokol. (2009) Thrombophilic patterns of coagulation factors in lupus. Lupus 18:5, pages 400-406.
Crossref
Crossref
Yuki Tsuruta, Keiko Uchida, Mitsuyo Itabashi, Wako Yumura & Kosaku Nitta. (2009) Antiphospholipid Antibodies and Renal Outcomes in Patients with Lupus Nephritis. Internal Medicine 48:21, pages 1875-1880.
Crossref
Crossref
Guillermo Ruiz-Irastorza & Munther A. Khamashta. 2009. Antiphospholipid Syndrome in Systemic Autoimmune Diseases. Antiphospholipid Syndrome in Systemic Autoimmune Diseases
185
191
.
Joan T. Merrill. 2009. Antiphospholipid Syndrome in Systemic Autoimmune Diseases. Antiphospholipid Syndrome in Systemic Autoimmune Diseases
169
183
.
Michelle Petri, Rachel Abuav, Dimitrios Boumpas, Fiona Goldblatt, David Isenberg, Grant J. Anhalt, Victoria P. Werth & R. John Looney. 2010. A Clinician's Pearls and Myths in Rheumatology. A Clinician's Pearls and Myths in Rheumatology
131
159
.
Jacob H. RandXiao-Xuan WuAnthony S. QuinnPojen P. Chen, James J. Hathcock & Douglas J. Taatjes. (2008) Hydroxychloroquine directly reduces the binding of antiphospholipid antibody–β2-glycoprotein I complexes to phospholipid bilayers. Blood 112:5, pages 1687-1695.
Crossref
Crossref
N. Costedoat-Chalumeau, G. Leroux, Z. Amoura & J.-C. Piette. (2008) Hydroxychloroquine dans le traitement du lupus: le renouveau. La Revue de Médecine Interne 29:9, pages 735-737.
Crossref
Crossref
Małgorzata Wisłowska. (2008) Cardiac involvement in systemic lupus erythematosusZmiany w sercu u chorych na toczeń rumieniowaty układowy. Annales UMCS, Medicina 63:1, pages 25-31.
Crossref
Crossref
MD Lockshin & RHWM Derksen. (2008) New developments in lupus-associated antiphospholipid syndrome. Lupus 17:5, pages 443-446.
Crossref
Crossref
G Ruiz-Irastorza & MA Khamashta. (2008) Hydroxychloroquine: the cornerstone of lupus therapy. Lupus 17:4, pages 271-273.
Crossref
Crossref
Kittiwan Choojitarom, Orawan Verasertniyom, Kitti Totemchokchyakarn, Kanokrat Nantiruj, Vasant Sumethkul & Suchela Janwityanujit. (2007) Lupus nephritis and Raynaud’s phenomenon are significant risk factors for vascular thrombosis in SLE patients with positive antiphospholipid antibodies. Clinical Rheumatology 27:3, pages 345-351.
Crossref
Crossref
Guillermo Ruiz-Irastorza & Munther A. Khamashta. (2007) The treatment of antiphospholipid syndrome: A harmonic contrast. Best Practice & Research Clinical Rheumatology 21:6, pages 1079-1092.
Crossref
Crossref
Wendy Lim & Mark A Crowther. (2007) Antiphospholipid antibiodies: a critical review of the literature. Current Opinion in Hematology 14:5, pages 494-499.
Crossref
Crossref
Sunil Kalia & Jan P Dutz. (2007) New concepts in antimalarial use and mode of action in dermatology. Dermatologic Therapy 20:4, pages 160-174.
Crossref
Crossref
Wendell A Wilson & Nigel Harris. 2007. Recurrent Pregnancy Loss. Recurrent Pregnancy Loss
119
126
.
A. TANAY, E. LEIBOVITZ, A. FRAYMAN, R. ZIMLICHMAN & D. GAVISH. (2007) Vascular Elasticity of Systemic Lupus Erythematosus Patients Is Associated with Steroids and Hydroxychloroquine Treatment. Annals of the New York Academy of Sciences 1108:1, pages 24-34.
Crossref
Crossref
D. WARE BRANCH & ALEXANDRA GROSVENOR Eller. (2006) Antiphospholipid Syndrome and Thrombosis. Clinical Obstetrics & Gynecology 49:4, pages 861-874.
Crossref
Crossref
Shawnna L Patterson, Marian P LaMonte, Jamal A Mikdashi, Stuart T Haines & Marcie J Hursting. (2006) Anticoagulation Strategies for Treatment of Ischemic Stroke and Antiphospholipid Syndrome: Case Report and Review of the Literature. Pharmacotherapy 26:10, pages 1518-1525.
Crossref
Crossref
Lai-Shan Tam, Edmund K. Li & Brian Tomlinson. (2006) Premature Atherosclerosis in Systemic Lupus Erythematosus: Pathogenesis and Therapeutic Considerations. Hong Kong Journal of Nephrology 8:2, pages 48-54.
Crossref
Crossref
G Ruiz-IrastorzaM-V Egurbide, J-I Pijoan, M Garmendia, I Villar, A Martinez-Berriotxoa, J-G Erdozain & C Aguirre. (2016) Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 15:9, pages 577-583.
Crossref
Crossref
N. Costedoat-Chalumeau, Z. Amoura, J.-S. Hulot, P. Lechat & J.-C. Piette. (2006) Faut-il doser l'hydroxychloroquine chez les patients lupiques ?. La Revue de Médecine Interne 27:9, pages 655-657.
Crossref
Crossref
Rosa M Andrade & Graciela S Alarcón. (2006) Antimalarials in systemic lupus erythematosus: benefits beyond disease activity. Future Rheumatology 1:2, pages 225-233.
Crossref
Crossref
Yasumasa Ikeda, Shusuke Yagi, Hiroshi Yamaguchi, Mitsunori Fujimura, Shunji Hashizume, Ken-ichi Aihara, Masashi Akaike, Hiroyuki Azuma & Toshio Matsumoto. (2006) Intra-Vascular Ultrasound Findings of Diffuse Coronary Atherosclerotic Change in Systemic Lupus Erythematosus With Secondary Antiphospholipid Syndrome. Circulation Journal 70:8, pages 1082-1085.
Crossref
Crossref
M Petri. (2016) Lupus in Baltimore: evidence-based ‘clinical pearls’ from the Hopkins Lupus Cohort. Lupus 14:12, pages 970-973.
Crossref
Crossref
M.C. Amigo-Castañeda. (2005) Tratamiento del síndrome antifosfolipídico, ¿a quién, cuándo y cuánto tiempo?. Reumatología Clínica 1, pages S52-S58.
Crossref
Crossref
Bridget Griffiths, Marta Mosca & Caroline Gordon. (2005) Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Practice & Research Clinical Rheumatology 19:5, pages 685-708.
Crossref
Crossref
Chi Chiu Mok, Sandy Shuk Kuen Tang, Chi Hung To & Michelle Petri. (2005) Incidence and risk factors of thromboembolism in systemic lupus erythematosus: A comparison of three ethnic groups. Arthritis & Rheumatism 52:9, pages 2774-2782.
Crossref
Crossref
Antonella Afeltra, Marta Vadacca, Laura Conti, Sara Galluzzo, Anna P. Mitterhofer, Giovanni M. Ferri, Flavia Del Porto, Domenico Caccavo, Giuseppe M. Gandolfo & Antonio Amoroso. (2005) Thrombosis in systemic lupus erythematosus: Congenital and acquired risk factors. Arthritis & Rheumatism 53:3, pages 452-459.
Crossref
Crossref
Candice Marie C. REYES & Sandra V. NAVARRA. (2005) Risk factors for stroke among Filipino patients with systemic lupus erythematosus. APLAR Journal of Rheumatology 8:1, pages 19-22.
Crossref
Crossref
Lisa R. Sammaritano. (2005) Antiphospholipid Syndrome: Review. Southern Medical Journal 98:6, pages 617-625.
Crossref
Crossref
Barri J. Fessler, Graciela S. Alarcón, Gerald McGwin, Jeffrey Roseman, Holly M. Bastian, Alan W. Friedman, Bruce A. Baethge, Luis Vilá & John D. Reveille. (2005) Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis & Rheumatism 52:5, pages 1473-1480.
Crossref
Crossref
Anna Wozniacka & Daniel P McCauliffe. (2005) Optimal Use of Antimalarials in Treating Cutaneous Lupus Erythematosus. American Journal of Clinical Dermatology 6:1, pages 1-11.
Crossref
Crossref
Silvia S. Pierangeli, Mariano Vega-Ostertag, Azzudin E. Gharavi & E. Nigel Harris. 2005. Molecular Autoimmunity. Molecular Autoimmunity
377
391
.
A Martínez-Berriotxoa, G Ruiz-Irastorza, M-V Egurbide, M Rueda & C Aguirre. (2016) Homocysteine, antiphospholipid antibodies and risk of thrombosis in patients with systemic lupus erythematosus. Lupus 13:12, pages 927-933.
Crossref
Crossref
María Teresa Camps García, Antonio Fernández Nebro, Carolina Díaz Cobos, Manuel Haro Liger, Miguel Ángel Barón Ramos & Enrique de Ramón Garrido. (2004) Manifestaciones clínicas y alteraciones inmunológicas en pacientes con síndrome antifosfolipídico. Presentación de 112 casos. Medicina Clínica 123:12, pages 466-470.
Crossref
Crossref
Sergio M. A. Toloza, Jeffrey M. Roseman, Graciela S. Alarcón, Gerald McGwinJr.Jr., América G. Uribe, Barri J. Fessler, Holly M. Bastian, Luis M. Vilá & John D. Reveille. (2004) Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXII. Predictors of time to the occurrence of initial damage. Arthritis & Rheumatism 50:10, pages 3177-3186.
Crossref
Crossref
Gabriella Moroni, Donatella Ventura, Paola Riva, Paola Panzeri, Silvana Quaglini, Giovanni Banfi, Paola Simonini, Rossella Bader, Pier Luigi Meroni & Claudio Ponticelli. (2004) Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis. American Journal of Kidney Diseases 43:1, pages 28-36.
Crossref
Crossref
Silvia S. Pierangeli, Mariano Vega-Ostertag & E. Nigel Harris. (2004) Intracellular signaling triggered by antiphospholipid antibodies in platelets and endothelial cells: a pathway to targeted therapies. Thrombosis Research 114:5-6, pages 467-476.
Crossref
Crossref
Arun ChakrabartyTania Phillips. (2016) Leg Ulcers of Unusual Causes. The International Journal of Lower Extremity Wounds 2:4, pages 207-216.
Crossref
Crossref
Robert A. S. Roubey. (2003) New approaches to prevention of thrombosis in the antiphospholipid syndrome: Hopes, trials, and tribulations. Arthritis & Rheumatism 48:11, pages 3004-3008.
Crossref
Crossref
&NA;. (2003) Treat juvenile-onset systemic lupus erythematosus according to disease severity. Drugs & Therapy Perspectives 19:3, pages 11-15.
Crossref
Crossref
Stephanie L Perry & Thomas L Ortel. (2003) Clinical and laboratory evaluation of thrombophilia. Clinics in Chest Medicine 24:1, pages 153-170.
Crossref
Crossref
Theodore E. Warkentin, William C. Aird & Jacob H. Rand. (2003) Platelet-Endothelial Interactions: Sepsis, HIT, and Antiphospholipid Syndrome. Hematology 2003:1, pages 497-519.
Crossref
Crossref
Eun Young Lee, Chang-Keun Lee, Tae Hoon Lee, Son Mi Chung, Seong Ho Kim, You Sook Cho, Bin Yoo & Hee-Bom Moon. (2003) Does the anti-β2-glycoprotein I antibody provide additional information in patients with thrombosis?. Thrombosis Research 111:1-2, pages 29-32.
Crossref
Crossref
Marta Valls Roc & Alejandro Olivé. (2003) Síndrome antifosfolipídico. Piel 18:2, pages 78-84.
Crossref
Crossref
Agustín Martínez-Berriotxoa, Guillermo Ruiz-Irastorza, María Victoria Egurbide Arberas, Miguel Rueda Gutiérrez & Ciriaco Aguirre Errasti. (2003) Homocisteína plasmática en pacientes con lupus eritematoso sistémico. Medicina Clínica 120:18, pages 681-685.
Crossref
Crossref
Rastislav Kucinsky, Irene J. Tan & Fred Rosner. (2002) Intramuscular Bleeding as a Complication of Anticoagulation Treatment in a Patient With Systemic Lupus Erythematosus and Antiphospholipid Syndrome. JCR: Journal of Clinical Rheumatology 8:6, pages 346-349.
Crossref
Crossref
J-C Piette, A Sbaï & C Francès. (2016) Warning: thalidomide-related thrombotic risk potentially concerns patients with lupus. Lupus 11:2, pages 67-70.
Crossref
Crossref
Luis Carre??o, Francisco Javier L??pez-Longo, Carlos Manuel Gonz??lez & Indalecio Monteagudo. (2002) Treatment Options for Juvenile-Onset Systemic Lupus Erythematosus. Pediatric Drugs 4:4, pages 241-256.
Crossref
Crossref
C J M Frijns, R H W M Derksen, P H G De Groot, A Algra & R Fijnheer. (2001) Lupus anticoagulant and history of thrombosis are not associated with persistent endothelial cell activation in systemic lupus erythematosus. Clinical and Experimental Immunology 125:1, pages 149-154.
Crossref
Crossref
Michelle Petri. (2001) MANAGEMENT OF THROMBOSIS IN ANTIPHOSPHOLIPID ANTIBODY SYNDROME. Rheumatic Disease Clinics of North America 27:3, pages 633-642.
Crossref
Crossref
Joan T. Merrill. (2001) WHICH ANTIPHOSPHOLIPID ANTIBODY TESTS ARE MOST USEFUL?. Rheumatic Disease Clinics of North America 27:3, pages 525-549.
Crossref
Crossref
R A Levy, V S Vilela, M J Cataldo, R C Ramos, J LMB Duarte, B R Tura, E MN Albuquerque & N R Jesús. (2016) Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus 10:6, pages 401-404.
Crossref
Crossref
Outi Vaarala. 2001. Vascular Manifestations of Systemic Autoimmune Diseases. Vascular Manifestations of Systemic Autoimmune Diseases.
B. Gail Macik, Jacob H. Rand & Barbara A. Konkle. (2001) Thrombophilia: What's a Practitioner to Do?. Hematology 2001:1, pages 322-338.
Crossref
Crossref
B. Gail Macik, Jacob H. Rand & Barbara A. Konkle. (2001) Thrombophilia: What's a Practitioner to Do?. Hematology 2001:1, pages 322-338.
Crossref
Crossref
T. A. Brighton & C. N. Chesterman. (2008) The clinical significance of antiphospholipid antibodies in patients without autoimmune disease. Australian and New Zealand Journal of Medicine 30:6, pages 693-703.
Crossref
Crossref
Mary-Carmen Amigo & Munther A. Khamashta. (2000) ANTIPHOSPHOLIPID (HUGHES) SYNDROME IN SYSTEMIC LUPUS ERYTHEMATOSUS. Rheumatic Disease Clinics of North America 26:2, pages 331-348.
Crossref
Crossref
Michelle Petri. (2000) HOPKINS LUPUS COHORT. Rheumatic Disease Clinics of North America 26:2, pages 199-213.
Crossref
Crossref
Michelle Petri. (2000) Treatment of the antiphospholipid antibody syndrome: Progress in the last five years?. Current Rheumatology Reports 2:3, pages 256-261.
Crossref
Crossref
M Petri. (2016) Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort. Lupus 9:3, pages 170-175.
Crossref
Crossref
O. Vaarala. 2000. Hughes Syndrome. Hughes Syndrome
172
178
.
S Kiraz, İ Ertenli, M Benekli, İ C Haznedaroğul, M Çalgüneri, İ Çelik, Ş Apraş & Ş Kirazlil. (2016) Clinical significance of hemostatic markers and thrombomodulin in systemic lupus erythematosus: evidence for a prothrombotic state. Lupus 8:9, pages 737-741.
Crossref
Crossref
Khalid Qushmaq, John Esdaile & Dana V. Devine. (1999) Thrombosis in systemic lupus erythematosus: The role of antiphospholipid antibody. Arthritis & Rheumatism 12:3, pages 212-219.
Crossref
Crossref
S. Jacobsen, J. Petersen, S. Ullman, P. Junker, A. Voss, J. M. Rasmussen, U. Tarp, L. H. Poulsen, G. van Overeem Hansen, B. Skaarup, T. M. Hansen, J. Pødenphant & P. Halberg. (1998) A multicentre study of 513 Danish patients with systemic lupus erythematosus. II. Disease mortality and clinical factors of prognostic value. Clinical Rheumatology 17:6, pages 478-484.
Crossref
Crossref
O. Vaarala. (2016) Editorial. Lupus 6:6, pages 489-490.
Crossref
Crossref